Forskolin

製品コードS2449 別名:Coleonol

Forskolin化学構造

分子量(MW):410.5

Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.

サイズ 価格(税別)  
JPY 23240.00
JPY 18260.00
JPY 44820.00
JPY 61420.00
JPY 94620.00

カスタマーフィードバック(2)

  • Eur J Cancer 2014 50(7), 1310-20. Forskolin purchased from Selleck.

    Measurement of cAMP accumulation in INS-1 cells. (A) INS-1, or (B) INS-1 transfected with murine GPR109A for 24 h, or (C) INS-1 transfected with human GPR109A for 24 h were incubated in DMEM (2.5 mM glucose) media with or without PTX (100 ng/ml) for 24 h. Cells were then incubated in KRB supplemented with 2.5 mM glucose, 500 μM IBMX, 10 μM forskolin, and with/without 10 or 100 μM NA for 1 h. After lysis with HCl (0.1 M), cells were sonicated and spun. The supernatants were saved for cAMP measurement by ELISA. (D) Reduction of cAMP accumulation in INS-1 and INS-1 cells transfected with GPR109A in the presence of 10 or 100 μM NA. White bar: INS-1 cells, grey bar: INS-1 cells transfected with murine GPR109A; black bar: INS-1 cells transfected with human GPR109A. (∗ and #p < 0.05, ∗ and ##p < 0.001). (n = 5).

    Gen Comp Endocrinol, 2016, 237:98-108. Forskolin purchased from Selleck.

製品安全説明書

cAMP阻害剤の選択性比較

生物活性

製品説明 Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.
ターゲット
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
体外試験

Forskolin increases cAMP levels in preparations of membranes, cells, or tissues. Forskolin not only activates AC but also interacts with certain other proteins, including glucose transporters and ion channels. Forskolin is able to promote activation of nine different transmembrane iso-forms of AC, albeit with somewhat less efficacy for AC9, which could be used to provides a means to identify and quantify high-affinity binding sites, i.e., G-proteins (Gs)–AC complexes. Activation of s by GPCRs contributes to Forskolin-stimulated cAMP generation in cells because of s-Forskolin potentiation of AC activity. [1] Forskolin stimulates adenylate cyclase activity without interacting with cell surface receptors. Forskolin's potentiation of cAMP in turn inhibits basophil and mast cell degranulation and histamine release, lowers blood pressure and intraocular pressure, inhibits platelet aggregation, promotes vasodilation, bronchodilation, and thyroid hormone secretion, and stimulates lipolysis in fat cells. Forskolin inhibits the binding of platelet-activating factor (PAF), independently of cAMP formation, which may be a result of Forskolin's direct effect on PAF or via interference with PAF binding to receptor sites. Forskolin also appears to have an effect on several membrane transport proteins, and inhibits glucose transport in erythrocytes, adipocytes, platelets, and other cells. Forskolin is used to treat with glaucoma. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 M1qxO2Z2dmO2aX;uJGF{e2G7 MVGxNEDPxE1? MVO2JIg> M{jsfolv[3KnYYPld{BxcG:|cHjvdplt[XSrb36gc4Yhd3[ncnX4dJJme3OnZDDLUGhNOyCjdDDTOFM{ NVfD[mQ3OjZ2M{W0PVg>
Mo-DCs MlrDSpVv[3Srb36gRZN{[Xl? MY[1NEDPxE1? NYD0ZWdsOjUkgJno MWLwdo9ud3SnczDJUE0zOyCycn;keYN1cW:wIHnuJJRp\SC|dYDldo5ifGGwdDDv[kB7gW2xc3HuJJN1cW23bHH0[YQhVW9vRFPzxsA> NVTyR2hEOjZ2MUK5OFg>
RBMECs  M1PtO2Z2dmO2aX;uJGF{e2G7 M3HKeVXDqM7:TR?= MnrJNeKhcA>? M3jEWoJtd2OtczD0bIUhWmGlMTDpcoFkfGm4YYTpc44hcW6mdXPl[EBjgSCHTVHQMWlK NVnO[lNDOjZ|NUiwN|k>
INA-6 M2i0OmNmdGxiVnnhZoltcXS7IFHzd4F6 NVuySIV1OC1zMECg{txO M2\2flcz6oDLaB?= MXPpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= NHrLNZMzPjNyNk[yOC=>
OPM-2 MUfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NIfjbGkxNTFyMDFOwG0> M2\qUlcz6oDLaB?= MlrYbY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm= NVXGepN4OjZ|ME[2NlQ>
U266 M{KwWmNmdGxiVnnhZoltcXS7IFHzd4F6 M2nYZ|AuOTByIN88US=> NXf1[XppPzMkgJno M{jQcIlv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5 NEnGcZAzPjNyNk[yOC=>
H929 NIrOUppE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MYOwMVExOCEQvF2= M373S|cz6oDLaB?= NGTVRplqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> NUnzSFdYOjZ|ME[2NlQ>
RPMI 8226 M1;4U2NmdGxiVnnhZoltcXS7IFHzd4F6 NUnESmoxOC1zMECg{txO Ml3GO|LjiImq MUnpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= MnXWNlY{ODZ4MkS=
MDCK  NHrkcGFHfW6ldHnvckBCe3OjeR?= MnLnNVAhyrWP NYnTZW5ZOjRiaB?= M1S2OWROW09? NIXlT492eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCWR1[t{tIyKGGwZDDDWGdHyqB? NGHiVYYzPjJyMkO1Ni=>
MDCK  M13DS2Z2dmO2aX;uJGF{e2G7 NWPqVYJVOTBiwsXN NYi1RXkyOjRiaB?= Ml7vSG1UVw>? MmC1bY5pcWKrdIOgeIhmKGmwY4LlZZNm\CCneIDy[ZN{cW:wIH;mJGZPKGOjdYPl[EBjgSCWR1[t{tIy NF73TVUzPjJyMkO1Ni=>
Spinal cords  NGTHZVhHfW6ldHnvckBCe3OjeR?= Mme3NeKh|ryP MkPTN|AhdWmw NYO1XJREe3SrbYXsZZRmeyClQV3QJIxmfmWucx?= MonwNlYyOjZ7Mk[=
BeWo  NF;ZNWFHfW6ldHnvckBCe3OjeR?= MX:yOgKBkc7:TR?= M1z6O|I1NzR6L{eyJIg> MlfjcIVi\HNidH:gZY4hcW6lcnXhd4UhcW5idHjlJIV5eHKnc4Ppc44hd2Zib4To[ZIh\nW|aX;uJI1iemuncoO= MVGyOlA2OzV2OR?=
bovine oocytes NYnI[mpRTnWwY4Tpc44hSXO|YYm= MX:xNFDDqM7:TR?= Mn[1NVLDqGh? NWfMOlNWcW6qaXLpeJMhfGinIHXm[oVkfCCxZjDOVHBCKGGwZD;vdkBPWFCFIITvJJN1cW23bHH0[UBz\XO3bYD0bY9vKG:oIH3lbY9{cXN? MnXwNlYxPTF4MUG=
Caco-2  M{TLN2Z2dmO2aX;uJGF{e2G7 NFvsVHUxNjFxMT:xNEDPxE1? NFrsN2UzOMLibXnu M{LNUolv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG|ZTDpckBqdnS{YXPlcIx2dGG{IHPBUXAhdGW4ZXzz NEPhS2gzPjB2OUGwNi=>
Caco-2  NHPJSGhHfW6ldHnvckBCe3OjeR?= MlHLNE4yNzFxMUCg{txO M1TRSVI1KGh? MofZbY5kemWjc3XzJG1TWDJicILveIVqdiCuZY\lcC=> M4LDeFI3ODR7MUCy
AML-12  MmDLSpVv[3Srb36gRZN{[Xl? Mon3NlAh|ryP MVqzJIg> NFT6blV2eHKnZ4XsZZRmeyC2aHWgdIhwe3Cqb4L5cIF1cW:wIHzleoVteyCjdDDUbJIuPDFzIHHu[EBU\XJvNEmz NGS1OFkzPjB2OEm4OS=>
AML-12  NGT6enpHfW6ldHnvckBCe3OjeR?= NYe0Zmg4OjBizszN NYDncFN2OS16IHi= NU\BPIpLcW6lcnXhd4V{KGeudXPvd4UheHKxZIXjeIlwdg>? MmO1NlYxPDh7OEW=
AML-12  MluySpVv[3Srb36gRZN{[Xl? MljZNlAh|ryP MnXkN{Bp M4PxNJVxNXKnZ4XsZZRme8LiUHfjNYEtyqCSZYDjb{wh[W6mwrDHOpBkyqCvUl7BJIxmfmWucx?= MXGyOlA1QDl6NR?=
AML-12  NGDZelJHfW6ldHnvckBCe3OjeR?= NFnvU4szOCEQvF2= NHHY[5k{KGh? M{nlcolv\HWlZYOgeIhmKGSncHjvd5Bpd3K7bHH0bY9vKG:oIFPSWGMzyqB? NF[3N|kzPjB2OEm4OS=>
RBMECs M3LXSGZ2dmO2aX;uJGF{e2G7 NUfacXN{PcLizszN NEjoemkyKGh? NVjJZo9xcW6qaXLpeJMhTU2DUD3JTU1qdmS3Y3XkJIlv[WO2aY\heIlwdiCxZjDSZZAyyqB? NEm3OmozPjB2NE[2Ny=>
EndoC-βH1 MWXGeY5kfGmxbjDBd5NigQ>? MoG4OeKh|ryP NGnC[GwyKGh? NEDXTmZxd3SnboTpZZRmeyCpbIXjc5NmNWmwZIXj[YQhcW6|dXzpckB{\WO{ZYTpc44hcW5idHjlJJBz\XOnbnPlJI9nKGeudXPvd4U> NHzOVFEzPjB{OEW2Ni=>
EndoC-βH1 NELDeW1HfW6ldHnvckBCe3OjeR?= MWq1xsDPxE1? MkjkNUBp M3vGboxm[WS|IITvJIEhe3S{b37nJINCVVBiaX7jdoVie2V? M4\W[lI3ODJ6NU[y
SH-SY5Y MVPGeY5kfGmxbjDBd5NigQ>? M{HRRVMxKM7:TR?= MYCzNEBucW5? M4i3[mROW09? M37GVJNq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBi[3SrdnH0bY9vKG:oIGDLRS=> NXr6ZYZnOjZyMkWxN|c>
PC-3 M1LhZmZ2dmO2aX;uJGF{e2G7 MnnGOFAhyrWP NX;0VXhSOiCq NHvtZVlFVVOR M3PCWIxm[WS|IITvJHBROkFiYXP0bZZifGmxbh?= NUS4ZXRkOjZyMkO4N|Y>
PC-3 NVXCcJRZS2WubDDWbYFjcWyrdImgRZN{[Xl? M4TFTFQxKML3TR?= MoTGNlQwPDhxN{KgbC=> Mmn0SG1UVw>? MW\k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlidHnt[UBl\XCnbnTlcpRtgQ>? NF\mOVAzPjB{M{izOi=>
SCG M3nKd2Z2dmO2aX;uJGF{e2G7 MX[yNEDPxE4EoB?= MVTEUXNQ MnO5doV3\XK|aXLsfUB{fXCycnXzd4V{KEmNVjD3bZRpKGFiSVO1NEBw\iB{ND60JO69VQ>? NHrjfmczPTl4MkGzNi=>
HEK-293 MlLNSpVv[3Srb36gRZN{[Xl? M4nMRlM2KM7:TdMg Ml73SG1UVw>? NXjDdlVHcW6mdXPld{BiKGOxboPwbYN2d3W|IPMAoIlv[WO2aY\heIlwduLCnTDv[kB1cGViS4[yMlEh[3W{cnXueC=> NXvheoYxOjV7NkKxN|I>
SCG MWrGeY5kfGmxbjDBd5NigQ>? NF7zNnMyODBizszNxsA> MXTEUXNQ MVry[YR2[2W|IITo[UBmgGOrdHHibYxqfHlib3[gV2NIKG6ndYLvcpM> MoTmNlU6PjJzM{K=
PCCL3 NFm1XolHfW6ldHnvckBCe3OjeR?= NU\EXWFFOTBiwsXN M1zDeVI1KGh? M{LoZ4VvcGGwY3XzJGR2V3h{IIDyc41wfGW{IITyZY5{[3KrcITpc44h[WO2aY\peJnDqOLCix?= MX[yOVk3ODl3Nh?=
3T3-L1 preadipocytes M1PYe2Z2dmO2aX;uJGF{e2G7 NVnqb3hGOTBizszNxsA> NYLjV41JOTJiaB?= MojkbY5lfWOnczDDVmVDKHCqb4PwbI9zgWyjdHnvckBidmRiQz;FRnDPuiCneIDy[ZN{cW:w NHvQTmgzPTl{OEC1PC=>
H295R  NX;4[WdRTnWwY4Tpc44hSXO|YYm= Mo\KNVDDqM7:TR?= Ml7YOFjDqGh? MVTpcoNz\WG|ZYOgd5Rmem:rZDDt[ZRi[m:uaYTld{BqdiC2aHWgZY5lem:pZX6sJI1qdmW{YXzvMUBidmRiZ3z1Z49kd3K2aXPvbYQheGG2aIfhfZM> MlrrNlU5Pjl3NU[=
PBMC Mlu5SpVv[3Srb36gRZN{[Xl? NY\lPJVnPTEEoN88US=> M1HSPVI1yqCqwrC= MVPpcohq[mm2czD0bIUhcW6lcnXhd4VlKHOnY4LleIlwdiCxZjDUUmYhcW6mdXPl[EBjgSC2aHWgSHBG NVnMe2hIOjV6Nk[wO|k>
GLUTag  NXWzR|VVTnWwY4Tpc44hSXO|YYm= Ml;tNVDjiIoEtV2= MWewM|IwPCCq NWDoO3ZYe3SrbYXsZZRmeyCJTGCtNUB{\WO{ZYTpc44h[2:2cnXheIVlKHerdHigTWJOYA>? NHjsPWkzPTh|Mk[zNS=>
GLUTag  M3PCVWZ2dmO2aX;uJGF{e2G7 NIfwO|IyOOLCidM1US=> NVLtWGxvPCCq NVO3TXVVcW6lcnXhd4V{KHSqZTDwR3JGSiCuZY\lcJMhf2m2aDD0bIUhUUKPWB?= Mm\kNlU5OzJ4M{G=
BAECs MWfGeY5kfGmxbjDBd5NigQ>? M3L4TVI2KM7:TR?= MmfVNlQhcA>? NXPNV4V4\W6qYX7j[ZMhfGinIHHjeIl3[XSrb36gc4YhWFCDUt8xJIJ6KDVizszNJJJme3[ncnH0do9tNCCWNFjTMEBweiB2LWDBVC=> MVOyOVc6QDh{Nh?=
PC12 NF\rTGNHfW6ldHnvckBCe3OjeR?= MVyyOeKh|ryP NXPQ[Jk6PDhiaB?= M1fYWIFkfGm4YYTld{BkSU2S NXf6d2lbOjV5NkmzNFU>
GH3 M1PqSGZ2dmO2aX;uJGF{e2G7 MYexxsDPxE1? M3TSflYucA>? MnXOZZR1\W63YYTld{B1cGViY3;ydoVt[XSrb36gZoV1f2WnbjDQVmwh[W6mIFLtZYwyKGW6cILld5Nqd25? MkLYNlU4OjdyMUi=
GH3 NWHuNmdyTnWwY4Tpc44hSXO|YYm= MXKxxsDPxE1? MofnOk1p MYHpcoR2[2W|IGDSUEBidmRiQn3hcFEtKGK3dDDuc5QhS2yxY3usJI1TVkFiZYjwdoV{e2mxbh?= NILwZ2IzPTd{N{CxPC=>
BeWo MWTGeY5kfGmxbjDBd5NigQ>? M1zyPFEx6oDMzszNxsA> NWrVXo91PzJiaB?= M2HIXmROW09? NUHQSHdqdWWmaXH0[ZMhSmWZbzDj[YxtKGSrZn\ldoVvfGmjdHnvci=> NIHyTFczPTdzM{SyOS=>
oocytes NFXKfJJHfW6ldHnvckBCe3OjeR?= NGrQTmY2KM7:TR?= MXOyOEBp NUX0PIxJ[XS2ZX71ZZRmeyC{aD3pcpN2dGmwIHHjeIlwdiCxbjDvc4N6fGViR2\CSEB{cWewaX\pZ4FvfGy7wrC= M1;TTVI2PzB5OEW0
SC MonpSpVv[3Srb36gRZN{[Xl? NHqxepgxNjVizszN NUDtTGpKOjRiaB?= Mmq4cYlucWOtczD0bIUh\W[oZXP0JI9nKGODTWCgZY5idG:pczDvckBQOSCjbnSgUWJRKGW6cILld5Nqd25? MYWyOVcxPTh5NB?=
SC NXXib5d3TnWwY4Tpc44hSXO|YYm= NXLOcnpyOC53IN88US=> NEX0ToE4OiCq MmfRbY5kemWjc3XzJIJwfGhiS4LvfE0zOCCjbnSgU|Eh\XiycnXzd4lwdiCrbjDhfI9vNXKnbHH0[YQhW0O|IHL1eEBwdmy7IFvyc5guOjEEoB?= M3zh[lI2PzB3OEe0
UACC-647  MVvGeY5kfGmxbjDBd5NigQ>? NUniU5p3TE2VTx?= M{L1OYxm[WS|IITvJIEhemm|ZTDpckBkSU2SIHzleoVteyBqRVO1NOKhRcLiMkCuN|nDqM7:TTm= NInp[lAzPTdyM{CyOS=>
UACC-647  NFvCc2FHfW6ldHnvckBCe3OjeR?= NHvRXpkyOMLizszN NYC1bnh2OTVibXnu MlrYSG1UVw>? MkfqbY5pcWKrdIOgSXJMKHCqb4PwbI9zgWyjdHnvci=> MXKyOVcxOzB{NR?=
UACC-647  NVfZNWM1TnWwY4Tpc44hSXO|YYm= MXSxNOKh|ryP NGGwSXUyPSCvaX6= MmPHSG1UVw>? Ml21bY5kemWjc3XzJIVGTjJicHjvd5Bpd3K7bHH0bY9vKGyndnXsd:Kh NGH1emIzPTdyM{CyOS=>
SH-SY5Y  NH\OTpJHfW6ldHnvckBCe3OjeR?= MYmxNOKh|ryP NYjl[IZYOcLiaNMg Mn7pbY5kemWjc3XzJGxWSyCjY4Tpeol1gQ>? NYLz[W5jOjV3OUe0N|M>
SH-SY5Y  NYT2S4FpTnWwY4Tpc44hSXO|YYm= MkjpNVDDqM7:TR?= NX\4dXl7OcLiaNMg M1TSOYlv[3KnYYPld{BCT0NzIH3SUmEhdGW4ZXy= NHjKe20zPTV7N{SzNy=>
hADSCs NH\ydXFHfW6ldHnvckBCe3OjeR?= M4fvSFXjiIoEtV2= Ml3zN|AhdWmw M4LvV4lv[3KnYYPld{BkSU2SIHzleoVtew>? Mn\6NlU2QTF7MEi=
HEK293  NHWyO2dHfW6ldHnvckBCe3OjeR?= NE\4bJA26oDLwsXN MVSzNEBucW5? MWfpcoNz\WG|ZYOgZ2FOWCCuZY\lcJM> MVKyOVU6OTlyOB?=
3T3-L1 NUfPSYNtTnWwY4Tpc44hSXO|YYm= MnLiNk42NzVizszN M3\4UFI1KGkEoB?= Mn3Nd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiQWTHUEBxem:2ZXnuJIV5eHKnc4Ppc44h[XRiYXzsJIRwe2W|IITld5Rm\A>? MX:yOVU6ODV7Nx?=
OCI-Ly1  M{jvPGZ2dmO2aX;uJGF{e2G7 NH[zbXI1OMLizszN MU[xxsBpyqB? NF7xSJZFVVOR MYHpcoR2[2W|IITo[UBqdmO{ZX3lcpQhd2ZiY1HNVEBkd26lZX70doF1cW:wcx?= NGK4UlQzPTV5NkKyNC=>
OCI-Ly18  MnrVSpVv[3Srb36gRZN{[Xl? MXu0NOKh|ryP M4T3Z|HDqGkEoB?= NIezcopFVVOR NXXVcmxYcW6mdXPld{B1cGViaX7jdoVu\W62IH;mJINCVVBiY3;uZ4VvfHKjdHnvcpM> MWWyOVU4PjJ{MB?=
BeWo M2\WdmZ2dmO2aX;uJGF{e2G7 MYeyNOKhyrWP MYK0POKhcA>? NHjJXJVFVVOR NVz2V|c2cW6lcnXhd4V{KHSqZTDkbYZn\XKnboTpZZRqd25ib3[gRoVYdyClZXzsdy=> M4fiPFI2PTZ4N{Sw
BeWo NGLGemVHfW6ldHnvckBCe3OjeR?= M{Tl[FIxyqEEtV2= NXXpeJByPDkEoHi= MXfEUXNQ MmSxbY5kemWjc3XzJJRp\SCjZHjld4lwdiCxZjDUTHAuOSCvb37vZ5l1\XN? MkK3NlU2PjZ5NEC=
LNCaP  NF\CfJpHfW6ldHnvckBCe3OjeR?= MX2xNOKh|ryP NEfOZW0yOiCqwrC= NHzMXHRFVVOR MnTEbY5lfWOnczDhJIRz[W2jdHnjJIlv[3KnYYPlJI9nKEOURVKxJIFkfGm4aYT5 MXSyOVU1QDB7OR?=
ThGCs  MkPSSpVv[3Srb36gRZN{[Xl? MmL5NVDjiIsQvF2= NGXTfGE16oDMaB?= MkXYZZVodWWwdIOgTGlHOUFibHX2[Yx{KHSqYYSge4Vz\SC|dHnteYxifGWmIHL5JGNwS2x{ NUHjOo1mOjV2M{OwNlc>
ThGCs  MlzqSpVv[3Srb36gRZN{[Xl? MnO3NVDjiIsQvF2= NIfKeo816oDMaB?= M3jiSYlv[3KnYYPld{BEd0OuMj3pcoR2[2WmIFXEUlLDqGenbnWg[ZhxemW|c3nvci=> NILMenIzPTR|M{CyOy=>
ThGCs  NF7He5ZHfW6ldHnvckBCe3OjeR?= NIjOWGQyOOLCit88US=> Ml\jN{Bp NHjzdG9qdmirYnn0d{B1cGViZX\m[YN1KG:oIFiyU|Ihd25iRVTONkBuWk6D MorwNlU1OzNyMke=
RBMECs MnfySpVv[3Srb36gRZN{[Xl? M1Hyc|AvODVxMD61M|Uh|ryP NHexVHoxNjJ3IHi= MnHLbY5kemWjc3XzJINCVVBiY3;uZ4VvfHKjdHnvci=> MYSyOVQyPjZ3MR?=
RBMECs MVXGeY5kfGmxbjDBd5NigQ>? MVy1xsDPxE1? MnzxNUBp Mnv0Zoxw[2u|IITo[UBi[3SrdnH0bY9vKG:oIGLoc2EwWk:FSzDpcoR2[2WmIHL5JGVOSVBvSVm= NHrKeZczPTRzNk[1NS=>
RBMECs MnfsSpVv[3Srb36gRZN{[Xl? NImxdYg2yqEQvF2= MoXhNUBp MYfwdoV3\W62czD0bIUhTU2DUD3JTU1qdmS3Y3XkJHRGTVJidnHseYUh\GWlcnXhd4U> NF\uZ48zPTRzNk[1NS=>
RBMECs Mme3SpVv[3Srb36gRZN{[Xl? M3vzXFXDqM7:TR?= Mn;kNUBp M2PySZBz\X[nboTzJJRp\SCrbnPy[YF{\SCrbjDIVnAh\my3eDDhZ5Jwe3NidHjlJGJVSiCrbnT1Z4VlKGK7IDDFUWFRNUmL NWfycHFkOjV2MU[2OVE>
RBMECs NVHXfnAyTnWwY4Tpc44hSXO|YYm= MnrnOeKh|ryP MWqxJIg> Ml\ObY5pcWKrdIOgeIhmKGSnY4LlZZNm\CCxZjDhcY92dnRib3[gXm8uOSCrbjDNSpMhcW6mdXPl[EBjgSCHTVHQMWlK NXL6dVVzOjV2MU[2OVE>
RBMECs MYDGeY5kfGmxbjDBd5NigQ>? NFzkenk2yqEQvF2= NEfvVIQyKGh? NYX6UmV4emW4ZYLz[ZMhfGinIHPoZY5o\XNiaX6gXm8uOSCmaYP0doljfXSrb36gd4VmdiC5aYToJGVOSVBvSVmgeJJm[XSvZX70 NELN[okzPTRzNk[1NS=>
RBMECs NHj6PFdHfW6ldHnvckBCe3OjeR?= Mn:5OeKh|ryP NF:xZncyKGh? NGGyOIxjdG:la4OgeIhmKEWPQWCtTWkucW6mdXPl[EBkcGGwZ3WgbY4hVUyFIIDoc5NxcG:{eXzheIlwdg>? NUTvWHZ7OjV2MU[2OVE>
RBMECs M3y3ZmZ2dmO2aX;uJGF{e2G7 NYe0TZFIPcLizszN MVuxJIg> NWjCbGl3[myxY3vzJJRp\SCjY4TpckBkgXSxc3vlcIV1d25icnXhdpJidmenbXXueEB{\WWwIIfpeIghTU2DUD3JTUB1emWjdH3lcpTDqA>? M{TaXVI2PDF4NkWx
Primary bovine chondrocytes MlTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVGwS5l4Pc7:TR?= M{DjdlQ5KGh? NFTnUIJz\X[ncoPld{B1cGViaX7obYJqfG:{eTDl[oZm[3Rib3[gZ4Vt\WOxeHniJI9vKHC{b3zp[oVz[XSrb36gbY4h\3Kxd4ToJJBt[XSnIHPoc45lem:leYTldy=> NVj1Zm9lOjV2ME[wNVY>
EM1  MY\GeY5kfGmxbjDBd5NigQ>? MW[xOgKBks7:TR?= MUi0PEBp NUXkVXF[emWmdXPld{B1cGViZYjwdoV{e2mxbjDv[uKhVEmIwrDvduKhWFSJU{NCpIlvyqCFQVzSMUBwesLiRWDBR|Iue2muZX7j[YQhTU1zIHPlcIx{yqB? MlvZNlU{Pzh4NkG=
BeWo  NGfEdVFHfW6ldHnvckBCe3OjeR?= MUOyNOKhyrWP NEjv[FU1QMLiaNMg M{H5XmROW00EoB?= NFfQXpNqdmO{ZXHz[ZMhfGinIHLleIEucEOJIILlcIVie2V? NWXOW3Y6OjV|NkKyOlA>
BeWo  NGH4cWpHfW6ldHnvckBCe3OjeR?= M1u0ZlIxyqEEtV2= NXfRcYdPPDkEoHlCpC=> MV7EUXNQyqB? M3LBU4Rwf26{ZXf1cIF1\XNidHjlJIxmfmWuIH;mJHROTU2IMU[= NYD2N4RvOjV|NkKyOlA>
BeWo  NHf4[3FHfW6ldHnvckBCe3OjeR?= MnLrNlDDqML3TR?= NVS4O5k3PDkEoHlCpC=> NFnI[4xFVVORwrC= MUfkc5dvemWpdXzheIV{KHSqZTDs[ZZmdCCxZjDHR20uOQ>? NE\2NpEzPTN4MkK2NC=>
granulosa cells MlvvSpVv[3Srb36gRZN{[Xl? NH3ufpYyOCEQvF2= NHq4WlcyOi9{NDDo MlzubY5kemWjc3XzJJRp\SCuZY\lcJMhd2cEoGLHV|LDqG2UTlG= Mom1NlU{OzlzMEW=
granulosa cells MUPGeY5kfGmxbjDBd5NigQ>? MlrnNVAh|ryP MV:xNk8zPCCq M4rkTYlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIILldI9zfGW{IHHjeIl3cXS7IH\vdkB1cGVibH;u[4V{fCCocnHncYVvfCBq4pkSPFU1NytzOGLHV|IvVFWFKR?= NIqyc4czPTN|OUGwOS=>
granulosa cells MYrGeY5kfGmxbjDBd5NigQ>? M361eVExKM7:TR?= NGTyVpIzPCCq NULSU|VEcW6lcnXhd4V{KHSqZTDpcpRmdnOrdImgc4YhTE6DL4Dyc5RmcW5iY3;tdIxmgA>? Ml;ZNlU{OzlzMEW=
granulosa cells NHfIepZHfW6ldHnvckBCe3OjeR?= Mn3BNVAh|ryP NH;wPZAzPCCq MYPpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCUR2OyJJBzd22xdHXyJIFkfGm4aYT5 MoXuNlU{OzlzMEW=
SK-N-AS  NIC1eItE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1vTWlExKM7:TdMg MXKyOE81QCCq NI\4WFlmdmijbnPld{B1cW2nLXTldIVv\GWwdHz5JINmdGy3bHHyJJZq[WKrbHn0feKh NX;EcmE6OjV{Nk[wOlM>
SK-N-AS  M2DEbWZ2dmO2aX;uJGF{e2G7 M1q1RlExKM7:TdMg M1vpV|I1KGh? NXfJ[nFmcW6lcnXhd4V{KHSqZTDjRW1RKGyndnXsd:Kh NWLyOWtSOjV{Nk[wOlM>
SK-N-AS  MXLGeY5kfGmxbjDBd5NigQ>? NXHzWoUyOTBizszNxsA> M4fPTVI1KGh? M{j3Wolv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBkgWOuaX6gSFE> NWO1bWM1OjV{Nk[wOlM>
SK-N-AS  MWPGeY5kfGmxbjDBd5NigQ>? NInWdZAyOCEQvF5CpC=> NInvcJU{OCCvaX6= MnrybY5lfWOnczDwbI9{eGixconsZZRqd25ib3[g{tIu[2G2ZX7pckApe2W{Nke1LUwheC2JU1uz{tIhMHOnckmpJIFv\CClb37jc41qfGGwdDDobYdp\XJibHX2[Yx{KG:oIHHjeIl3\SxidX7wbI9{eGixconsZZRm\CxizsKtZ4F1\W6rbh?= M3fUbVI2OjZ4ME[z
SK-N-AS  NVLZZnFNTnWwY4Tpc44hSXO|YYm= NGTrSmUyOCEQvF5CpC=> NHfXXlcyOC9|MD:2NEBucW5? NYO3T3llcW6lcnXhd4V{KGyndnXsd{Bw\iCyLd8yMYNifGWwaX6gLJNmejZ5NTmgZY5lKGmwZIXj[ZMh[WOldX31cIF1cW:wIH;mJJAu|rJvY3H0[Y5qdiBqc3XyOlc2MSCrbjCodIVzcSmwdXPs[YFzKHKnZ3nvcpM> MlXRNlUzPjZyNkO=
SK-N-SH M1z5[mNmdGxiVnnhZoltcXS7IFHzd4F6 MlPqNVAh|ryPwrC= Ml\nOFghcA>? NFPjdFJmdmijbnPld{BUUy2QLWPIJI5mfXKxYnzhd5RwdWFiY3XscEB3cWGkaXzpeJk> MVeyOVI3PjB4Mx?=
HEK‐CFTR M4WyVGZ2dmO2aX;uJGF{e2G7 NFrKWGwz6oDVNUFCpO69VQ>? MUiwMVEzKG2rbh?= NWnTNG06TE2VT9Mg MlLTbY5lfWOnczDhJIRwe2YkgKDk[ZBmdmSnboSgbY9lcWSnIHXm[ox2gMLi NEn0NnIzPTJ4M{KwOy=>
L6 MVHGeY5kfGmxbjDBd5NigQ>? NG\rUpY1OCEEtV2= M1zTdVI1KGh? MX3pcohq[mm2czDEUWgyNWmwZIXj[YQhSWu2IHHjeIl3[XSrb36= MYmyOVI1PzV3MB?=
MIN6  M3[4SWZ2dmO2aX;uJGF{e2G7 MYKxNEDPxE4EoB?= Ml\PN{Bp NULjeWJicW6lcnXhd4V{KER|IH3SUmEh\XiycnXzd4lwdg>? NHHaVpMzPTJ2MUGyOC=>
ventricular cardiomyocytes  MYnGeY5kfGmxbjDBd5NigQ>? NYXCNnF5OC5yMT2xNEDPxE1? NF3LdYZqdmO{ZXHz[ZMhKGODTWCgZYNkfW23bHH0bY9v MWGyOVIxOzFzMx?=
ventricular cardiomyocytes  NF\HeIFHfW6ldHnvckBCe3OjeR?= MlTjNE4xOS1zMDFOwG0> M{fwNYV3d2unczDhckBqdm:2cn;wbYMhemW|cH;ud4UhOTJywsGxOUUh[WKxdnWgZoF{[Wxid3n0bEBidiCHQ{WwxsBw\iB{LkKgxtVO NVS3VHR2OjV{MEOxNVM>
BeWo  NWHMSo5OTnWwY4Tpc44hSXO|YYm= NWLPVWVmOjBiwsXN NH;iZoM1QCCq M13IOmROW00EoB?= Ml70bY5lfWOnczDj[YxtKG[3c3nvci=> MkfPNlUyQDR2N{e=
THP-1  MWDGeY5kfGmxbjDBd5NigQ>? NHXJcmkyNzFyIN88US=> MoixNuKhcA>? NHvxfllFVVORwrC= NUfEU3pxe3WycILld5NmeyCPQ2CtNUBxem:mdXP0bY9vyqB? NEOzTGIzPTF3NEi4Ni=>
Huh-7 MXTGeY5kfGmxbjDBd5NigQ>? Ml;yNE0zOCEQvF2= MkHJNkBpyqB? M1nIUZJme3WudIOgbY4h[SCmb4PlMYRmeGWwZHXueEBqdmO{ZXHz[UBqdiClLV35Z{BmgHC{ZYPzbY9vKGG2IITo[UBxem:2ZXnuJIFv\CCvUl7BJIxmfmWucx?= MoO1NlUyODl6M{S=
C6 M{jXb2Z2dmO2aX;uJGF{e2G7 M3zaRlExKM7:TdMg MXiyNEBucW5? M4mwfIlv[3KnYYPld{BkSU2SIHHjZ5VufWyjdHnvci=> Mn2wNlUxPjl2MUe=
SW480 MorkSpVv[3Srb36gRZN{[Xl? NGLQVYg1OMLizszN NVjOXYRbPDkEoHi= Ml7OSG1UVw>? MXnhZ5RqfmG2ZYOgVHAzSQ>? Moq3NlQ6QTd2NUG=
HT-29  NIDCTYRHfW6ldHnvckBCe3OjeR?= NIC5TGk1OMLizszN M134eFQ5yqCq MXHEUXNQ Mn;NZYN1cX[jdHXzJHBROkF? MoKxNlQ6QTd2NUG=
SW480 M{nsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWC0NOKh|ryP NITx[IExNTd{IHi= M3HB[WROW09? MUTpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 NYfwTJBLOjR7OUe0OVE>
HT-29  NFzoeoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF2zTVA1OMLizszN M3H1RlAuPzJiaB?= M{fFVGROW09? MnfkbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> MnL4NlQ6QTd2NUG=
SW480 NEXK[GpHfW6ldHnvckBCe3OjeR?= NUPPNJJlPDEEoN88US=> M3n5TVch\A>? MnnlSG1UVw>? Mm\DdoVlfWOnczDjc4xwdm:|cHjldoUh\m:{bXH0bY9vKGOjcHHibYxqfHoEoB?= MUCyOFk6PzR3MR?=
HT-29  M1rEbmZ2dmO2aX;uJGF{e2G7 MmHOOFDDqM7:TR?= NUPNbG82PyCm M17xPWROW09? NIHNdWdz\WS3Y3XzJINwdG:wb4PwbIVz\SCob4LtZZRqd25iY3HwZYJqdGm2edMg Mn7ENlQ6QTd2NUG=
SW480 M4jWVmFxd3C2b4Ppd{BCe3OjeR?= MnHhOFDDqM7:TR?= Mnv1OFjDqGh? MoDESG1UVw>? MlXibY5lfWOnczDhckBi[3SrdnH0bY9vKG:oIHPhd5Bie2ViMz:3 MmrnNlQ6QTd2NUG=
HT-29  MX;BdI9xfG:|aYOgRZN{[Xl? NWCwclVlPDEEoN88US=> NHfkR3Y1QMLiaB?= M3PsbWROW09? NWrPfpVscW6mdXPld{BidiCjY4TpeoF1cW:wIH;mJINie3Cjc3WgN{84 NELlXWgzPDl7N{S1NS=>
SW480 MmrHRZBweHSxc3nzJGF{e2G7 M1f6cVQxyqEQvF2= NXvwcpUyPDkEoHi= NXLRWnIxTE2VTx?= MUnpcoR2[2W|IHPoZY5o\XNiaX6geIhmKHCqb4PwbI9zgWyjdHnvckB{fGG2dYOgc4YhWFB{QTD0ZZJo\XS| NVS1cllFOjR7OUe0OVE>
HT-29  NVvMbFY6SXCxcITvd4l{KEG|c3H5 MXK0NOKh|ryP MXi0POKhcA>? MnHUSG1UVw>? NVzGNGp3cW6mdXPld{BkcGGwZ3XzJIlvKHSqZTDwbI9{eGixconsZZRqd25ic4TheJV{KG:oIGDQNmEhfGG{Z3X0dy=> M37tOVI1QTl5NEWx

多くの細胞株試験データを見る場合、クリックしてください

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.75 mM)
Ethanol 37 mg/mL (90.13 mM)
Water Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 410.5
化学式

C22H34O7

CAS No. 66575-29-9
保管
別名 Coleonol

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01254006 Completed Glaucoma University of Roma La Sapienza|vingolo enzo maria|domanico daniela|salvatore serena null --

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

cAMPシグナル伝達経路

Tags: Forskolinを買う | Forskolin ic50 | Forskolin供給者 | Forskolinを購入する | Forskolin費用 | Forskolin生産者 | オーダーForskolin | Forskolin化学構造 | Forskolin分子量 | Forskolin代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID